Considerations and recommendations from the ISMRM diffusion study group for preclinical diffusion MRI: Part 2-Ex vivo imaging: Added value and acquisition

dc.contributor.authorSchilling, Kurt G.
dc.contributor.authorGrussu, Francesco
dc.contributor.authorIanus, Andrada
dc.contributor.authorHansen, Brian
dc.contributor.authorHoward, Amy F. D.
dc.contributor.authorBarrett, Rachel L. C.
dc.contributor.authorAggarwal, Manisha
dc.contributor.authorMichielse, Stijn
dc.contributor.authorNasrallah, Fatima
dc.contributor.authorSyeda, Warda
dc.contributor.authorWang, Nian
dc.contributor.authorVeraart, Jelle
dc.contributor.authorRoebroeck, Alard
dc.contributor.authorBagdasarian, Andrew F.
dc.contributor.authorEichner, Cornelius
dc.contributor.authorSepehrband, Farshid
dc.contributor.authorZimmermann, Jan
dc.contributor.authorSoustelle, Lucas
dc.contributor.authorBowman, Christien
dc.contributor.authorTendler, Benjamin C.
dc.contributor.authorHertanu, Andreea
dc.contributor.authorJeurissen, Ben
dc.contributor.authorVerhoye, Marleen
dc.contributor.authorFrydman, Lucio
dc.contributor.authorvan de Looij, Yohan
dc.contributor.authorHike, David
dc.contributor.authorDunn, Jeff F.
dc.contributor.authorMiller, Karla
dc.contributor.authorLandman, Bennett A.
dc.contributor.authorShemesh, Noam
dc.contributor.authorAnderson, Adam
dc.contributor.authorMcKinnon, Emilie
dc.contributor.authorFarquharson, Shawna
dc.contributor.authorDell'Acqua, Flavio
dc.contributor.authorPierpaoli, Carlo
dc.contributor.authorDrobnjak, Ivana
dc.contributor.authorLeemans, Alexander
dc.contributor.authorHarkins, Kevin D.
dc.contributor.authorDescoteaux, Maxime
dc.contributor.authorXu, Duan
dc.contributor.authorHuang, Hao
dc.contributor.authorSantin, Mathieu D.
dc.contributor.authorGrant, Samuel C.
dc.contributor.authorObenaus, Andre
dc.contributor.authorKim, Gene S.
dc.contributor.authorWu, Dan
dc.contributor.authorLe Bihan, Denis
dc.contributor.authorBlackband, Stephen J.
dc.contributor.authorCiobanu, Luisa
dc.contributor.authorFieremans, Els
dc.contributor.authorBai, Ruiliang
dc.contributor.authorLeergaard, Trygve B.
dc.contributor.authorZhang, Jiangyang
dc.contributor.authorDyrby, Tim B.
dc.contributor.authorJohnson, G. Allan
dc.contributor.authorCohen-Adad, Julien
dc.contributor.authorBudde, Matthew D.
dc.contributor.authorJelescu, Ileana O.
dc.contributor.departmentNeurology, School of Medicine
dc.date.accessioned2025-05-20T09:58:57Z
dc.date.available2025-05-20T09:58:57Z
dc.date.issued2025
dc.description.abstractThe value of preclinical diffusion MRI (dMRI) is substantial. While dMRI enables in vivo non-invasive characterization of tissue, ex vivo dMRI is increasingly being used to probe tissue microstructure and brain connectivity. Ex vivo dMRI has several experimental advantages including higher SNR and spatial resolution compared to in vivo studies, and enabling more advanced diffusion contrasts for improved microstructure and connectivity characterization. Another major advantage of ex vivo dMRI is the direct comparison with histological data, as a crucial methodological validation. However, there are a number of considerations that must be made when performing ex vivo experiments. The steps from tissue preparation, image acquisition and processing, and interpretation of results are complex, with many decisions that not only differ dramatically from in vivo imaging of small animals, but ultimately affect what questions can be answered using the data. This work represents "Part 2" of a three-part series of recommendations and considerations for preclinical dMRI. We describe best practices for dMRI of ex vivo tissue, with a focus on the value that ex vivo imaging adds to the field of dMRI and considerations in ex vivo image acquisition. We first give general considerations and foundational knowledge that must be considered when designing experiments. We briefly describe differences in specimens and models and discuss why some may be more or less appropriate for different studies. We then give guidelines for ex vivo protocols, including tissue fixation, sample preparation, and MR scanning. In each section, we attempt to provide guidelines and recommendations, but also highlight areas for which no guidelines exist (and why), and where future work should lie. An overarching goal herein is to enhance the rigor and reproducibility of ex vivo dMRI acquisitions and analyses, and thereby advance biomedical knowledge.
dc.eprint.versionFinal published version
dc.identifier.citationSchilling KG, Grussu F, Ianus A, et al. Considerations and recommendations from the ISMRM diffusion study group for preclinical diffusion MRI: Part 2-Ex vivo imaging: Added value and acquisition. Magn Reson Med. 2025;93(6):2535-2560. doi:10.1002/mrm.30435
dc.identifier.urihttps://hdl.handle.net/1805/48255
dc.language.isoen_US
dc.publisherWiley
dc.relation.isversionof10.1002/mrm.30435
dc.relation.journalMagnetic Resonance in Medicine
dc.rightsAttribution 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourcePMC
dc.subjectAcquisition
dc.subjectBest practices
dc.subjectDiffusion MRI
dc.subjectDiffusion tensor
dc.subjectEx vivo
dc.subjectMicrostructure
dc.subjectOpen science
dc.subjectPreclinical
dc.subjectProcessing
dc.subjectTractography
dc.titleConsiderations and recommendations from the ISMRM diffusion study group for preclinical diffusion MRI: Part 2-Ex vivo imaging: Added value and acquisition
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Schilling2025Considerations-CCBY.pdf
Size:
8.02 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.04 KB
Format:
Item-specific license agreed upon to submission
Description: